Aligos Therapeutics Inc (ALGS)
1.10
-0.03 (-2.65%)
USD |
NASDAQ |
May 19, 15:58
Aligos Therapeutics Enterprise Value: -134.98M for May 18, 2022
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 18, 2022 | -134.98M |
| May 17, 2022 | -134.12M |
| May 16, 2022 | -136.68M |
| May 13, 2022 | -133.27M |
| May 12, 2022 | -133.27M |
| May 11, 2022 | -136.68M |
| May 10, 2022 | -133.70M |
| May 09, 2022 | -136.26M |
| May 06, 2022 | -138.82M |
| May 05, 2022 | -136.26M |
| May 04, 2022 | -130.28M |
| May 03, 2022 | -129.85M |
| May 02, 2022 | -128.15M |
| April 29, 2022 | -132.84M |
| April 28, 2022 | -130.71M |
| April 27, 2022 | -129.43M |
| April 26, 2022 | -128.15M |
| April 25, 2022 | -123.88M |
| April 22, 2022 | -123.45M |
| April 21, 2022 | -123.88M |
| April 20, 2022 | -119.61M |
| April 19, 2022 | -120.46M |
| April 18, 2022 | -120.89M |
| April 14, 2022 | -117.04M |
| April 13, 2022 | -112.77M |
| Date | Value |
|---|---|
| April 12, 2022 | -111.92M |
| April 11, 2022 | -108.93M |
| April 08, 2022 | -106.37M |
| April 07, 2022 | -99.11M |
| April 06, 2022 | -96.55M |
| April 05, 2022 | -91.85M |
| April 04, 2022 | -94.84M |
| April 01, 2022 | -98.26M |
| March 31, 2022 | -91.43M |
| March 30, 2022 | -101.93M |
| March 29, 2022 | -99.58M |
| March 28, 2022 | -100.65M |
| March 25, 2022 | -93.39M |
| March 24, 2022 | -89.98M |
| March 23, 2022 | -71.62M |
| March 22, 2022 | -66.92M |
| March 21, 2022 | -69.06M |
| March 18, 2022 | -69.06M |
| March 17, 2022 | -73.33M |
| March 16, 2022 | -80.58M |
| March 15, 2022 | -89.98M |
| March 14, 2022 | -86.13M |
| March 11, 2022 | -80.16M |
| March 10, 2022 | -86.13M |
| March 09, 2022 | -81.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-138.82M
Minimum
May 06 2022
1.178B
Maximum
Dec 23 2020
438.41M
Average
482.03M
Median
Enterprise Value Benchmarks
| Natera Inc | 3.039B |
| Alnylam Pharmaceuticals Inc | 13.94B |
| Solid Biosciences Inc | -118.32M |
| Motus GI Holdings Inc | 2.616M |
| CEL-SCI Corp | 93.56M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.62M |
| Revenue (Quarterly) | 2.571M |
| Total Expenses (Quarterly) | 38.13M |
| EPS Diluted (Quarterly) | -0.84 |
| Profit Margin (Quarterly) | -1.39K% |
| Earnings Yield | -300.0% |
| Normalized Earnings Yield | -300.00 |